Compare IX & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | A |
|---|---|---|
| Founded | 1950 | 1999 |
| Country | Japan | United States |
| Employees | 51921 | N/A |
| Industry | Diversified Financial Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4B | 39.8B |
| IPO Year | N/A | 1999 |
| Metric | IX | A |
|---|---|---|
| Price | $31.87 | $120.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $161.47 |
| AVG Volume (30 Days) | 370.4K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.35% | 0.84% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | $11.91 | $8.45 |
| Revenue Next Year | $4.50 | $6.13 |
| P/E Ratio | ★ $12.93 | $113.79 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $19.79 | $101.20 |
| 52 Week High | $37.04 | $160.27 |
| Indicator | IX | A |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 57.93 |
| Support Level | $29.29 | $115.76 |
| Resistance Level | $37.04 | $122.75 |
| Average True Range (ATR) | 0.50 | 2.74 |
| MACD | 0.30 | 1.11 |
| Stochastic Oscillator | 80.99 | 86.55 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.